Market Closed -
Nyse
04:00:02 2024-04-24 pm EDT
Pre-market
08:11:48 am
48.86
USD
-0.27%
47.95
-1.86%
Bristol Myers Squibb : 2019-2020 Product Sales Summary
May 07, 2020 at 11:54 am EDT
BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
2019
2020
$ Change
% Change
1st Qtr
2nd Qtr
6 Months
3rd Qtr
9 Months
4th Qtr(b)
Year(b)
1st Qtr(c)
2nd Qtr
6 Months
3rd Qtr
9 Months
4th Qtr
Year
Qtr vs. Qtr
YTD vs. YTD
Qtr vs. Qtr
YTD vs. YTD
Prioritized Brands
Revlimid
$
-
$ -
$ -
$ -
$ -
$
1,299
$
1,299
$
2,915
$
2,915
$
2,915
N/A
N/A
Eliquis
1,925
2,042
3,967
1,928
5,895
2,034
7,929
2,641
716
716
37%
37%
Opdivo
1,801
1,823
3,624
1,817
5,441
1,763
7,204
1,766
(35)
(35)
(2)%
(2)%
Orencia
640
778
1,418
767
2,185
792
2,977
714
74
74
12%
12%
Pomalyst/Imnovid
-
-
-
-
-
322
322
713
713
713
N/A
N/A
Sprycel
459
544
1,003
558
1,561
549
2,110
521
62
62
14%
14%
Yervoy
384
367
751
353
1,104
385
1,489
396
12
12
3%
3%
Abraxane
-
-
-
-
-
166
166
300
300
300
N/A
N/A
Empliciti
83
91
174
89
263
94
357
97
14
14
17%
17%
Reblozyl
-
-
-
-
-
-
-
8
8
8
N/A
N/A
Inrebic
-
-
-
-
-
5
5
12
12
12
N/A
N/A
Established Brands
Baraclude
141
147
288
145
433
122
555
122
(19)
(19)
(13)%
(13)%
Vidaza
-
-
-
-
-
58
58
158
158
158
N/A
N/A
Other Brands(a)
487
481
968
350
1,318
356
1,674
418
(69)
(69)
(14)%
(14)%
Total
$
5,920
$
6,273
$
12,193
$
6,007
$
18,200
$
7,945
$
26,145
$
10,781
$
4,861
$
4,861
82%
82%
Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue. Other Brands includes $122 million relating to Celgene products in the three months ended March 31, 2020.
Includes Celgene product revenues from November 20, 2019 through December 31, 2019.
Includes Celgene product revenues for the three months ended March 31, 2020. Attachments
Original document
Permalink
Disclaimer
Bristol-Myers Squibb Company published this content on 07 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2020 15:53:09 UTC
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance
08:08am
MT
Bristol Myers: heavy quarterly loss on charges
08:08am
CF
Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss
07:53am
DJ
(BMY) BRISTOL MYERS SQUIBB Sees Fiscal Year 2024 EPS Range $0.40 - $0.70
07:35am
MT
Earnings Flash (BMY) BRISTOL MYERS SQUIBB Posts Q1 Revenue $11.87B, vs. Street Est of $11.45B
07:35am
MT
Futures Decline Pre-Bell Ahead of Earnings, Economic Reports; Asia Churns, Europe Down
07:02am
MT
Bristol Myers posts quarterly loss, revenue rises 5%
06:59am
RE
Futures falter as Meta Platforms weighs on megacaps
06:03am
RE
Germany's Evotec appoints Christian Wojczewski as CEO
Apr. 23
RE
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair
Apr. 23
MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand
Apr. 23
MT
Novartis raises targets for 2024
Apr. 23
CF
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates
Apr. 22
RE
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies
Apr. 22
MT
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares
Apr. 22
RE
Bristol Myers signs supply agreement with Cellares
Apr. 22
CF
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies
Apr. 22
RE
Bristol Myers Squibb and Cellares Announce Worldwide Capacity Reservation and Supply Agreement for Manufacture of CAR T Cell Therapies
Apr. 22
CI
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating
Apr. 22
MT
US FDA mandates label updates on CAR-T cancer therapies
Apr. 18
RE
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating
Apr. 18
MT
Pathios Therapeutics Limited announced a financing transaction
Apr. 17
CI
TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors
Apr. 16
CI
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors
Apr. 15
CI
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept
Apr. 15
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
More about the company
Last Close Price
48.86
USD
Average target price
56.2
USD
Spread / Average Target
+15.01%
Consensus
1st Jan change
Capi.
-4.77% 99.03B +25.61% 660B +23.21% 562B -5.24% 358B +16.49% 322B +8.28% 297B +12.32% 219B -9.57% 196B +6.48% 199B -8.75% 149B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1